In patients greater than age 65, more than 90% of aortic stenosis involves trileaflet valves which have developed heavy calcification. [5] In these instances the calcium deposits are thought to ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Q: My doctor heard a new heart murmur and suspected I have a narrowed valve due to aortic stenosis. I feel fine. Why did this ...

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Reference: Zhang B, Enriquez-Sarano M, Schaff HV, et al. Reactivation of oxidized soluble guanylate cyclase as a novel treatment strategy to slow progression of calcific aortic valve stenosis: ...

Source Reference: Lindman BR, El-Sabawi B "SGLT2 inhibition in aortic stenosis: a therapy for the ventricle, the valve, or both?" JACC Cardiovasc Interv 2025; DOI: 10.1016/j.jcin.2024.12.025.